WO2022224207 - METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS

National phase entry:
Publication Number WO/2022/224207
Publication Date 27.10.2022
International Application No. PCT/IB2022/053763
International Filing Date 22.04.2022
Title **
[English] METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS
[French] PROCÉDÉ DE TRAITEMENT DU SYNDROME DE DÉTRESSE RESPIRATOIRE AIGUË (SDRA) À L'AIDE DE CELLULES SOUCHES OU PRÉCURSEURS DE LA LIGNÉE MÉSENCHYMATEUSE
Applicants **
MESOBLAST INTERNATIONAL SARL
Inventors
ITESCU, Silviu
Priority Data
2021901214   23.04.2021   AU
2021902180   15.07.2021   AU
2022900260   09.02.2022   AU
2022900372   18.02.2022   AU
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3273
EPO Filing, Examination, Granting23513
Japan Filing, Examination, Granting3019
South Korea Filing, Examination, Granting3929
USA Filing, Examination, Granting9340
MasterCard Visa
Total: 43,074

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] The present disclosure relates to methods for treating or preventing Acute Respiratory Distress Syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).[French] La présente divulgation concerne un procédé de traitement ou de prévention du syndrome de détresse respiratoire aiguë (SDRA) chez un sujet en ayant besoin, ce procédé comprenant l'administration au sujet d'une composition comprenant des cellules souches ou précurseurs de la lignée mésenchymateuse (MLPSC).